Nova Eye Medical Limited
ELXMF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.03 | 0.05 | 0.03 |
| FCF Yield | -6.90% | -9.90% | -11.53% | -15.57% |
| EV / EBITDA | -24.85 | -7.37 | -19.34 | -6.53 |
| Quality | ||||
| ROIC | -7.90% | -13.34% | -3.18% | -30.74% |
| Gross Margin | 63.23% | 66.19% | 85.39% | 13.04% |
| Cash Conversion Ratio | 0.70 | 0.66 | 1.18 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.21% | -8.93% | -12.63% | -29.33% |
| Free Cash Flow Growth | 24.31% | 2.26% | 16.05% | -84.76% |
| Safety | ||||
| Net Debt / EBITDA | 1.32 | -0.22 | 1.82 | 0.33 |
| Interest Coverage | -26.30 | -346.00 | -13.55 | -467.17 |
| Efficiency | ||||
| Inventory Turnover | 2.14 | 1.00 | 0.45 | 2.13 |
| Cash Conversion Cycle | 29.43 | 52.49 | 61.36 | 19.07 |